Celularity Announces Participation in Upcoming Investor Conferences
September 06, 2022 16:10 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
August 09, 2022 16:10 ET
|
Celularity, Inc.
- Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancers - - Completed a $30 million...
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
July 27, 2022 08:00 ET
|
Celularity, Inc.
CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need U.S....
Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®
June 08, 2022 16:10 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell...
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
June 03, 2022 08:00 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell...
Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules
May 18, 2022 08:30 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell...
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 16:10 ET
|
Celularity, Inc.
Ongoing Phase 1 study of unmodified placental-derived natural killer (NK) cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) continues enrolling new cohorts to reflect adjustments to...
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 31, 2022 16:05 ET
|
Celularity, Inc.
Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) and glioblastoma multiforme (GBM) An ongoing Phase 1...
Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference
March 15, 2022 16:05 ET
|
Celularity, Inc.
FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic...
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
February 15, 2022 16:05 ET
|
Celularity, Inc.
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase 1/2a clinical...